KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

Background: Programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) inhibitors represent novel therapeutic options for advanced non-small cell lung cancer (NSCLC). However, approximately 50% of patients do not benefit from therapy and experience rapid disease progression. PD-L1 expression is the only...

Full description

Bibliographic Details
Main Authors:	Marika Cinausero, Noemi Laprovitera, Giovanna De Maglio, Lorenzo Gerratana, Mattia Riefolo, Marianna Macerelli, Michelangelo Fiorentino, Elisa Porcellini, Vanessa Buoro, Francesco Gelsomino, Anna Squadrilli, Gianpiero Fasola, Massimo Negrini, Marcello Tiseo, Manuela Ferracin, Andrea Ardizzoni
Format:	Article
Language:	English
Published:	SAGE Publishing 2019-11-01
Series:	Therapeutic Advances in Medical Oncology
Online Access:	https://doi.org/10.1177/1758835919885540

Similar Items

Genetic Characterization of Cancer of Unknown Primary Using Liquid Biopsy Approaches
by: Noemi Laprovitera, et al.
Published: (2021-06-01)

Rare and Insidious Toxicities from New Combination Therapies in Metastatic Renal Cell Cancer: Lessons Learned from Real-Practice
by: Arianna Dri, et al.
Published: (2022-09-01)

Cancer Site-Specific Multiple microRNA Quantification by Droplet Digital PCR
by: Noemi Laprovitera, et al.
Published: (2018-10-01)

Interplay between small and long non‐coding RNAs in cutaneous melanoma: a complex jigsaw puzzle with missing pieces
by: Mattia Riefolo, et al.
Published: (2019-01-01)

Cancer of Unknown Primary: Challenges and Progress in Clinical Management
by: Noemi Laprovitera, et al.
Published: (2021-01-01)

Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Kras Mutation in East Asian Populations: A Single-Center Cohort Study in Taiwan
by: Shang-Gin Wu, MD, PhD, et al.
Published: (2021-02-01)

Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
by: Véronique Hofman, MD, PhD, et al.
Published: (2023-02-01)

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence
by: Karim Rihawi, et al.
Published: (2017-09-01)

Breaking bad family ties: Pan-ERBB blockers inhibit KRAS driven lung tumorigenesis
by: Herwig P. Moll, et al.
Published: (2018-11-01)

Atezolizumab in a oort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal Subtyps (CHANCE trial)
by: Francesco Gelsomino, et al.
Published: (2020-07-01)

MicroRNA expression profiling with a droplet digital PCR assay enables molecular diagnosis and prognosis of cancers of unknown primary
by: Noemi Laprovitera, et al.
Published: (2021-10-01)

KRAS is a molecular determinant of platinum responsiveness in glioblastoma
by: Candida Zuchegna, et al.
Published: (2024-01-01)

Novel mutant KRAS addiction signature predicts response to the combination of ERBB and MEK inhibitors in lung and pancreatic cancers
by: Katarzyna M. Tyc, et al.
Published: (2023-03-01)

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3
by: Chong Sun, et al.
Published: (2014-04-01)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review
by: Marcello Tiseo, et al.
Published: (2011-12-01)

Chemotherapy in the treatment of thymic tumors
by: Marcello Tiseo, et al.
Published: (2011-12-01)

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
by: Morgensztern, D, et al.
Published: (2018)

New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event
by: Giuseppe Lamberti, et al.
Published: (2020-07-01)

Androgen Receptor Expression in Primary Nonsquamous Cell Rare-Variant Carcinomas of the Head and Neck
by: Siavash Rahimi MD, FRCPath, et al.
Published: (2017-06-01)

Multicenter study of carbon‐ion radiation therapy for nonsquamous cell carcinomas of the oral cavity
by: Hiroaki Ikawa, et al.
Published: (2019-09-01)

A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
by: Daichi Fujimoto, MD, et al.
Published: (2022-02-01)

Gemcitabine: Efficacy in the Treatment of Advanced Stage Nonsquamous Non-Small Cell Lung Cancer
by: Hidetoshi Hayashi, et al.
Published: (2011-01-01)

CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors
by: Filippo G. Dall’Olio, et al.
Published: (2020-10-01)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
by: Sebastian K Wandinger, et al.
Published: (2016-01-01)

Rationally co-targeting divergent pathways in KRAS wild-type colorectal cancers by CANscript technology reveals tumor dependence on Notch and Erbb2
by: Nilesh Brijwani, et al.
Published: (2017-05-01)

Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021
by: Lisa M. Hess, PhD, et al.
Published: (2022-06-01)

Bevacizumab in the treatment of nonsquamous non-small cell lung cancer: clinical trial evidence and experience
by: Laurent Greillier, et al.
Published: (2016-10-01)

An Epidemiologic study of Oral and Pharyngeal Nonsquamous Cell Malignant Tumors inKerman province, Iran
by: MR. Zarei, et al.
Published: (2007-03-01)

Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker
by: Giacomo Pelizzari, et al.
Published: (2019-08-01)

MET and Small-Cell Lung Cancer
by: Francesco Gelsomino, et al.
Published: (2014-10-01)

The autocrine loop of ALK receptor and ALKAL2 ligand is an actionable target in consensus molecular subtype 1 colon cancer
by: Martina Mazzeschi, et al.
Published: (2022-03-01)

Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis
by: Emi Dika, et al.
Published: (2021-05-01)

Does Pemetrexed Work in Targetable, Nonsquamous Non-Small-Cell Lung Cancer? A Narrative Review
by: Jin-Yuan Shih, et al.
Published: (2020-09-01)

The Study of Druggable Targets in Nonsquamous Non-Small-Cell Lung Cancer in the Middle East and North Africa
by: Abdul Rahman Jazieh, et al.
Published: (2019-02-01)

Deciphering the tumor microenvironment cell–infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC
by: Hao Chen, et al.
Published: (2022-06-01)

Bevacizumab for the treatment of nonsquamous non-small-cell lung cancer in Portugal: a retrospective, multicenter study
by: Estevinho F, et al.
Published: (2012-03-01)

Modulation of ErbB2 blockade in ErbB2-positive cancers: the role of ErbB2 Mutations and PHLDA1.
by: Guangyuan Li, et al.
Published: (2014-01-01)

First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
by: Debora Basile, et al.
Published: (2021-06-01)

ERBB1- and ERBB2-Positive Medullary Thyroid Carcinoma: A Case Report
by: Michele Minuto, et al.
Published: (2018-04-01)